n(g),n(g')-dimethyl-l-arginine has been researched along with Metabolic Syndrome in 32 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to assess the effects of virgin coconut oil (VCO) consumption on metabolic syndrome (MetS) components, as well as, asymmetric dimethylarginine (ADMA) in adults with MetS." | 9.41 | Effects of virgin coconut oil consumption on metabolic syndrome components and asymmetric dimethylarginine: A randomized controlled clinical trial. ( Asghari, S; Hosseinzadeh-Attar, MJ; Nikooei, P; Norouzy, A; Vasheghani-Farahani, A; Yaseri, M, 2021) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, is a risk factor for endothelial dysfunction, a common pathophysiological denominator for both atherogenesis and cardiac fibrosis." | 8.31 | The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome. ( Bełtowski, J; Czechowska, G; Fornal, E; Góralczyk, A; Korolczuk, A; Kozub, A; Marzec-Kotarska, B; Nikolaichuk, H; Pradiuch, A; Stachniuk, A; Trzpil, A; Wójcicka, G, 2023) |
| "Circulating levels of the endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA), are positively associated with the prevalence of metabolic syndrome (MetS) in cross-sectional investigations." | 8.02 | Associations of circulating dimethylarginines with the metabolic syndrome in the Framingham Offspring study. ( Atzler, D; Böger, RH; Duncan, MS; Hannemann, J; Maas, R; Moser, C; Schwedhelm, E; Vasan, RS; Xanthakis, V; Yola, IM, 2021) |
| " To evaluate whether there is an association between plasma ADMA concentrations and insulin resistance in Hispanic population, we identified metabolic syndrome NCEP-ATP III criteria and measured ADMA and L-arginine plasma concentrations in 147 Colombian young males consecutively included in a cross-sectional study." | 7.74 | Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. ( Böger, RH; Garcia, RG; López-Jaramillo, P; Maas, R; Perez, M; Schwedhelm, E, 2007) |
| "Increased circulating methylarginines (MA) have been linked to the metabolic syndrome to explain endothelial dysfunction and cardiovascular disease risk." | 7.73 | Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. ( Adegoke, OA; Chevalier, S; Gougeon, R; Lamarche, M; Marliss, EB; Morais, JA; Wu, G, 2006) |
| "Fluvastatin treatment for hypercholesterolemia in patients with MetS is associated with a decrease in serum ADMA levels at 6 weeks." | 6.73 | Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M, 2008) |
| "Metabolic syndrome has several comorbidities, which result in a high cardiometabolic risk." | 6.73 | Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. ( Asbún, J; Ceballos, G; Elisa, ZN; Emma, MN; Guzman, M; Hicks, J; Meaney, A; Meaney, E; Samaniego, V; Vela, A; Zempoalteca, JC, 2008) |
| " Endothelial dysfunction with impaired nitric oxide biosynthesis and decreased bioavailability has been implicated in insulin resistance syndrome and Type II (non-insulin-dependent) diabetes mellitus." | 6.41 | Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? ( Chan, JC; Chan, NN, 2002) |
| " This study aimed to assess the effects of virgin coconut oil (VCO) consumption on metabolic syndrome (MetS) components, as well as, asymmetric dimethylarginine (ADMA) in adults with MetS." | 5.41 | Effects of virgin coconut oil consumption on metabolic syndrome components and asymmetric dimethylarginine: A randomized controlled clinical trial. ( Asghari, S; Hosseinzadeh-Attar, MJ; Nikooei, P; Norouzy, A; Vasheghani-Farahani, A; Yaseri, M, 2021) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous modulator of endothelial function and oxidative stress, and increased levels of this molecule have been reported in some metabolic disorders and cardiovascular diseases." | 5.37 | Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: a model related to metabolic syndrome. ( Collin, B; Cottin, Y; Duvillard, L; Goirand, F; Guilland, JC; Korandji, C; Lauzier, B; Moreau, D; Rochette, L; Sicard, P; Vergely, C; Zeller, M, 2011) |
| " Endothelial dysfunction with impaired nitric oxide (NO) bioavailability has been implicated in insulin resistance and hypertension." | 5.37 | Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. ( Alarcón, LM; Contreras, A; Díaz, N; González, DR; Guzmán, L; Icaza, G; Leiva, E; Moore-Carrasco, R; Mujica, V; Palomo, I, 2011) |
| "Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthesis, is a risk factor for endothelial dysfunction, a common pathophysiological denominator for both atherogenesis and cardiac fibrosis." | 4.31 | The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome. ( Bełtowski, J; Czechowska, G; Fornal, E; Góralczyk, A; Korolczuk, A; Kozub, A; Marzec-Kotarska, B; Nikolaichuk, H; Pradiuch, A; Stachniuk, A; Trzpil, A; Wójcicka, G, 2023) |
| "Circulating levels of the endogenous inhibitor of nitric oxide synthase, asymmetric dimethylarginine (ADMA), are positively associated with the prevalence of metabolic syndrome (MetS) in cross-sectional investigations." | 4.02 | Associations of circulating dimethylarginines with the metabolic syndrome in the Framingham Offspring study. ( Atzler, D; Böger, RH; Duncan, MS; Hannemann, J; Maas, R; Moser, C; Schwedhelm, E; Vasan, RS; Xanthakis, V; Yola, IM, 2021) |
| " Patients with metabolic syndrome (MS) had lower activity of gluthatione peroxidase, higher asymmetric dimethyloarginine (ADMA) and oxidized LDL cholesterol (oxyLDL) in comparison to patients without MS." | 3.78 | Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy. ( Janas, R; Litwin, M; Niemirska, A; Płudowski, P; Skorupa, E; Sladowska-Kozłowska, J; Wawer, ZT; Wierzbicka, A, 2012) |
| " To evaluate whether there is an association between plasma ADMA concentrations and insulin resistance in Hispanic population, we identified metabolic syndrome NCEP-ATP III criteria and measured ADMA and L-arginine plasma concentrations in 147 Colombian young males consecutively included in a cross-sectional study." | 3.74 | Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. ( Böger, RH; Garcia, RG; López-Jaramillo, P; Maas, R; Perez, M; Schwedhelm, E, 2007) |
| "Increased circulating methylarginines (MA) have been linked to the metabolic syndrome to explain endothelial dysfunction and cardiovascular disease risk." | 3.73 | Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. ( Adegoke, OA; Chevalier, S; Gougeon, R; Lamarche, M; Marliss, EB; Morais, JA; Wu, G, 2006) |
| "Rosiglitazone (4 mg/d for 4 weeks and then 4 mg twice daily for 8 weeks), an insulin-sensitizing agent, was given to 7 insulin-resistant subjects with hypertension." | 3.71 | Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. ( Abbasi, F; Chu, JW; Cooke, JP; Lamendola, C; McLaughlin, TL; Reaven, GM; Stühlinger, MC; Tsao, PS, 2002) |
| "Fluvastatin treatment for hypercholesterolemia in patients with MetS is associated with a decrease in serum ADMA levels at 6 weeks." | 2.73 | Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. ( Oguz, A; Uzunlulu, M, 2008) |
| "Metabolic syndrome has several comorbidities, which result in a high cardiometabolic risk." | 2.73 | Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study. ( Asbún, J; Ceballos, G; Elisa, ZN; Emma, MN; Guzman, M; Hicks, J; Meaney, A; Meaney, E; Samaniego, V; Vela, A; Zempoalteca, JC, 2008) |
| " It is well established that a decreased bioavailability of nitric oxide (NO) contributes to endothelial dysfunction." | 2.43 | Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. ( Cooke, JP; Mondon, CE; Sydow, K, 2005) |
| " Endothelial dysfunction with impaired nitric oxide biosynthesis and decreased bioavailability has been implicated in insulin resistance syndrome and Type II (non-insulin-dependent) diabetes mellitus." | 2.41 | Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? ( Chan, JC; Chan, NN, 2002) |
| "Like rheumatoid arthritis, ankylosing spondylitis (AS) is also an inflammatory disease associated with accelerated atherosclerosis and the presence of metabolic syndrome (MeS) features." | 1.40 | IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy. ( Blanco, R; Carnero-López, B; Genre, F; Gómez-Acebo, I; González-Gay, MA; González-Juanatey, C; Llorca, J; López-Mejías, R; Miranda-Filloy, JA; Pina, T; Rueda-Gotor, J; Ubilla, B; Villar-Bonet, A, 2014) |
| "Insulin resistance was quantified by Homeostasis Model Assessment index." | 1.38 | Biological signatures of asymptomatic extra- and intracranial atherosclerosis: the Barcelona-AsIA (Asymptomatic Intracranial Atherosclerosis) study. ( Alzamora, MT; Arenillas, JF; Barallat, J; Dávalos, A; Dorado, L; Galán, A; Hernández, M; Jiménez, M; López-Cancio, E; Massuet, A; Millán, M; Reverté, S; Suñol, A, 2012) |
| "Asymmetric dimethylarginine (ADMA) is an endogenous modulator of endothelial function and oxidative stress, and increased levels of this molecule have been reported in some metabolic disorders and cardiovascular diseases." | 1.37 | Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: a model related to metabolic syndrome. ( Collin, B; Cottin, Y; Duvillard, L; Goirand, F; Guilland, JC; Korandji, C; Lauzier, B; Moreau, D; Rochette, L; Sicard, P; Vergely, C; Zeller, M, 2011) |
| " Endothelial dysfunction with impaired nitric oxide (NO) bioavailability has been implicated in insulin resistance and hypertension." | 1.37 | Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. ( Alarcón, LM; Contreras, A; Díaz, N; González, DR; Guzmán, L; Icaza, G; Leiva, E; Moore-Carrasco, R; Mujica, V; Palomo, I, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (43.75) | 29.6817 |
| 2010's | 14 (43.75) | 24.3611 |
| 2020's | 4 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Yola, IM | 1 |
| Moser, C | 1 |
| Duncan, MS | 1 |
| Schwedhelm, E | 2 |
| Atzler, D | 1 |
| Maas, R | 2 |
| Hannemann, J | 1 |
| Böger, RH | 2 |
| Vasan, RS | 1 |
| Xanthakis, V | 1 |
| Wójcicka, G | 1 |
| Pradiuch, A | 1 |
| Fornal, E | 1 |
| Stachniuk, A | 1 |
| Korolczuk, A | 1 |
| Marzec-Kotarska, B | 1 |
| Nikolaichuk, H | 1 |
| Czechowska, G | 1 |
| Kozub, A | 1 |
| Trzpil, A | 1 |
| Góralczyk, A | 1 |
| Bełtowski, J | 1 |
| Al-Abdulla, N | 1 |
| Bakhsh, A | 1 |
| Mannocci, F | 1 |
| Proctor, G | 1 |
| Moyes, D | 1 |
| Niazi, SA | 1 |
| Nikooei, P | 1 |
| Hosseinzadeh-Attar, MJ | 1 |
| Asghari, S | 1 |
| Norouzy, A | 1 |
| Yaseri, M | 1 |
| Vasheghani-Farahani, A | 1 |
| Uzunova, I | 1 |
| Kirilov, G | 1 |
| Zacharieva, S | 1 |
| Zlatareva, N | 1 |
| Kalinov, K | 1 |
| Lu, TM | 1 |
| Lee, TS | 1 |
| Lin, SJ | 1 |
| Chan, WL | 1 |
| Hsu, CP | 1 |
| Triches, CB | 1 |
| Mayer, S | 1 |
| Quinto, BMR | 1 |
| Batista, MC | 1 |
| Zanella, MT | 1 |
| Tomada, N | 1 |
| Tomada, I | 1 |
| Botelho, F | 1 |
| Pacheco-Figueiredo, L | 1 |
| Lopes, T | 1 |
| Negrão, R | 1 |
| Pestana, M | 1 |
| Cruz, F | 1 |
| Ballard, KD | 1 |
| Mah, E | 1 |
| Guo, Y | 1 |
| Pei, R | 1 |
| Volek, JS | 1 |
| Bruno, RS | 1 |
| Egert, S | 1 |
| Baxheinrich, A | 1 |
| Lee-Barkey, YH | 1 |
| Tschoepe, D | 1 |
| Wahrburg, U | 1 |
| Stratmann, B | 1 |
| Genre, F | 1 |
| López-Mejías, R | 1 |
| Rueda-Gotor, J | 1 |
| Miranda-Filloy, JA | 1 |
| Ubilla, B | 1 |
| Villar-Bonet, A | 1 |
| Carnero-López, B | 1 |
| Gómez-Acebo, I | 1 |
| Blanco, R | 1 |
| Pina, T | 1 |
| González-Juanatey, C | 1 |
| Llorca, J | 1 |
| González-Gay, MA | 1 |
| Oguz, A | 1 |
| Uzunlulu, M | 1 |
| Vida, G | 1 |
| Sulyok, E | 1 |
| Lakatos, O | 1 |
| Ertl, T | 1 |
| Martens-Lobenhoffer, J | 1 |
| Bode-Böger, SM | 1 |
| Thande, N | 1 |
| Rosenson, RS | 1 |
| Gamidov, SI | 1 |
| Mazo, EB | 1 |
| Gasanov, RV | 1 |
| Sotnikova, EM | 1 |
| Agrawal, A | 1 |
| Mabalirajan, U | 1 |
| Ahmad, T | 1 |
| Ghosh, B | 1 |
| Korandji, C | 1 |
| Zeller, M | 2 |
| Guilland, JC | 1 |
| Collin, B | 1 |
| Lauzier, B | 1 |
| Sicard, P | 1 |
| Duvillard, L | 1 |
| Goirand, F | 1 |
| Moreau, D | 1 |
| Cottin, Y | 2 |
| Rochette, L | 1 |
| Vergely, C | 1 |
| Siervo, M | 2 |
| Corander, M | 1 |
| Mander, AP | 1 |
| Browning, LM | 1 |
| Jebb, SA | 1 |
| Palomo, I | 1 |
| Contreras, A | 1 |
| Alarcón, LM | 1 |
| Leiva, E | 1 |
| Guzmán, L | 1 |
| Mujica, V | 1 |
| Icaza, G | 1 |
| Díaz, N | 1 |
| González, DR | 1 |
| Moore-Carrasco, R | 1 |
| Bluck, LJ | 1 |
| Sladowska-Kozłowska, J | 1 |
| Litwin, M | 1 |
| Niemirska, A | 1 |
| Płudowski, P | 1 |
| Wierzbicka, A | 1 |
| Skorupa, E | 1 |
| Wawer, ZT | 1 |
| Janas, R | 1 |
| López-Cancio, E | 1 |
| Galán, A | 1 |
| Dorado, L | 1 |
| Jiménez, M | 1 |
| Hernández, M | 1 |
| Millán, M | 1 |
| Reverté, S | 1 |
| Suñol, A | 1 |
| Barallat, J | 1 |
| Massuet, A | 1 |
| Alzamora, MT | 1 |
| Dávalos, A | 1 |
| Arenillas, JF | 1 |
| Chan, NN | 1 |
| Chan, JC | 1 |
| Marliss, EB | 1 |
| Chevalier, S | 1 |
| Gougeon, R | 1 |
| Morais, JA | 1 |
| Lamarche, M | 1 |
| Adegoke, OA | 1 |
| Wu, G | 1 |
| Sydow, K | 1 |
| Mondon, CE | 1 |
| Cooke, JP | 3 |
| Thomas, D | 1 |
| Cambou, JP | 1 |
| Danchin, N | 1 |
| Empana, JP | 1 |
| Ferrières, J | 1 |
| Jouven, X | 1 |
| Paillard, F | 1 |
| Valensi, P | 1 |
| Garcia, RG | 1 |
| Perez, M | 1 |
| López-Jaramillo, P | 1 |
| Potena, L | 1 |
| Ferrara, R | 1 |
| Mocarski, ES | 1 |
| Lewis, DB | 1 |
| Grigioni, F | 1 |
| Coccolo, F | 1 |
| Magnani, G | 1 |
| Fallani, F | 1 |
| Magelli, C | 1 |
| Valantine, HA | 1 |
| Branzi, A | 1 |
| Onat, A | 1 |
| Hergenç, G | 1 |
| Meaney, E | 1 |
| Vela, A | 1 |
| Samaniego, V | 1 |
| Meaney, A | 1 |
| Asbún, J | 1 |
| Zempoalteca, JC | 1 |
| Elisa, ZN | 1 |
| Emma, MN | 1 |
| Guzman, M | 1 |
| Hicks, J | 1 |
| Ceballos, G | 1 |
| Stühlinger, MC | 1 |
| Abbasi, F | 1 |
| Chu, JW | 1 |
| Lamendola, C | 1 |
| McLaughlin, TL | 1 |
| Reaven, GM | 1 |
| Tsao, PS | 1 |
| Nash, DT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat[NCT02482610] | 22 participants (Actual) | Interventional | 2016-06-30 | Completed | |||
| Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk[NCT02482675] | 23 participants (Actual) | Interventional | 2015-06-30 | Completed | |||
| Vasoprotective Activities of Low-Fat Milk in Individuals With Metabolic Syndrome[NCT01411293] | 21 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| Adiposity and Airway Inflammation in HIV-Associated Airway Disease[NCT02975258] | 102 participants (Actual) | Observational | 2015-09-30 | Completed | |||
| "A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. KYMES"[NCT01168700] | Phase 4 | 46 participants (Anticipated) | Interventional | 2009-11-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Biomarker of nitric oxide homeostasis is based on the assessment of total nitrite and nitrate concentrations. Changes relative to baseline were used to calculate area under the curve of total nitric oxide metabolites from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in nitric oxide homeostasis from 0 min to 180 min (i.e., AUC (NOx 0 min- 0 min, NOx 30 min-0 min, NOx 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of nitrite/nitrate for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -2229 |
| Glucose With Whole Fat Milk | -1240 |
| Glucose With Non-fat Milk | -1221 |
Glucose concentrations evaluated on the basis as change from baseline to calculate glucose area under the curve from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in glucose from 0 min to 180 min (i.e., AUC (glucose 0 min- 0 min, glucose 30 min-0 min, glucose 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of glucose for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | mg/dL*min (Mean) |
|---|---|
| Glucose | 6259 |
| Glucose With Whole Fat Milk | 4481 |
| Glucose With Non-fat Milk | 3408 |
MDA concentrations evaluated on the basis as change from baseline to calculate MDAarea under the curve from 0-180 min, i.e. Area Under the Curve (AUC) of change from baseline in MDA from 0 min to 180 min (i.e., AUC (MDA 0 min- 0 min, MDA 30 min-0 min, MDA 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of MDA for three hours (0, 30, 60, 90, 120, 150, 180 min)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | 54.9 |
| Glucose With Whole Fat Milk | 25.78 |
| Glucose With Non-fat Milk | 31.3 |
Flow mediated dilation (FMD) evaluated on the basis as change from baseline to calculate FMD area under the curve from 0-180 min, i.e. i.e. Area Under the Curve (AUC) of change from baseline in FMD from 0 min to 180 min (i.e., AUC (FMD 0 min- 0 min, FMD 30 min-0 min, FMD 60 min-0 min, etc) (NCT02482610)
Timeframe: Area under curve of FMD for three hours (0, 30, 60, 90, 120, 150, and 180 min)
| Intervention | %*min (Mean) |
|---|---|
| Glucose | -195.9 |
| Glucose With Whole Fat Milk | -6.181 |
| Glucose With Non-fat Milk | -5.629 |
Plasma 8-isoprostaglandin-F2a concentration, calculated as 8-isoprostaglandin-F2a AUC from 0-180 minutes (NCT02482675)
Timeframe: 8-isoprostaglandin-F2a area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | pg/mL*min (Mean) |
|---|---|
| Glucose | 2162.2 |
| Glucose With Non-fat Milk | -824.14 |
| Glucose With Whey Protein Isolate | -18.75 |
| Glucose With Sodium Caseinate | 229.14 |
Plasma 8-isoprostaglandin-F2a/Arachidonic acid concentration, calculated as 8-isoprostaglandin-F2a/Arachidonic acid AUC from 0-180 minutes (NCT02482675)
Timeframe: 8-isoprostaglandin-F2a/Arachidonic acid area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (pg/mL)/(ug/mL)*min (Mean) |
|---|---|
| Glucose | 10129 |
| Glucose With Non-fat Milk | -1655.2 |
| Glucose With Whey Protein Isolate | 2422.3 |
| Glucose With Sodium Caseinate | 3907.6 |
Arachidonic acid concentration, calculated as Arachidonic acid AUC from 0-180 minutes (NCT02482675)
Timeframe: Arachidonic acid area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | ug/mL*min (Mean) |
|---|---|
| Glucose | -2570 |
| Glucose With Non-fat Milk | -1358.4 |
| Glucose With Whey Protein Isolate | -2762.6 |
| Glucose With Sodium Caseinate | -2752.0 |
Plasma arginine concentration, calculated as ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -3922 |
| Glucose With Non-fat Milk | -1235 |
| Glucose With Whey Protein Isolate | 195 |
| Glucose With Sodium Caseinate | -189 |
Plasma ADMA/arginine concentration, calculated as ADMA/ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: ADMA/ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (nmol/L)/(umol/L)*min (Mean) |
|---|---|
| Glucose | 275 |
| Glucose With Non-fat Milk | 55 |
| Glucose With Whey Protein Isolate | 47 |
| Glucose With Sodium Caseinate | 25 |
Plasma CCK concentration, calculated as CCK AUC from 0-180 minutes (NCT02482675)
Timeframe: CCK area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | pmol/L*min (Mean) |
|---|---|
| Glucose | 89.67 |
| Glucose With Non-fat Milk | 422.87 |
| Glucose With Whey Protein Isolate | 352.5 |
| Glucose With Sodium Caseinate | 519.94 |
Plasma insulin concentration, calculated as insulin AUC from 0-180 minutes (NCT02482675)
Timeframe: Insulin area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | uIU/mL*min (Mean) |
|---|---|
| Glucose | 8179.7 |
| Glucose With Non-fat Milk | 8196.1 |
| Glucose With Whey Protein Isolate | 8654.6 |
| Glucose With Sodium Caseinate | 8656.9 |
Plasma MDA measured as MDA AUC from 0-180 minutes (NCT02482675)
Timeframe: Area under curve for MDA for three hours (0, 30, 60, 90, 120, 150, 180 min.) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | 66.5 |
| Glucose With Non-fat Milk | 43.2 |
| Glucose With Whey Protein Isolate | 46.4 |
| Glucose With Sodium Caseinate | 45.1 |
NOx AUC for 0-180 minutes (NCT02482675)
Timeframe: Area under curve for nitrite/nitrate for three hours (0, 30, 60, 90, 120, 180 min) (change from baseline)
| Intervention | umol/L*min (Mean) |
|---|---|
| Glucose | -1363 |
| Glucose With Non-fat Milk | 347 |
| Glucose With Whey Protein Isolate | -21 |
| Glucose With Sodium Caseinate | -57.2 |
Plasma glucose concentration from 0-180 minutes (NCT02482675)
Timeframe: Area under the curve for glucose for three hours (0, 30, 60, 90, 120, 180 minutes) (change from baseline)
| Intervention | mg/dL*min (Mean) |
|---|---|
| Glucose | 5828 |
| Glucose With Non-fat Milk | 4032 |
| Glucose With Whey Protein Isolate | 3340 |
| Glucose With Sodium Caseinate | 3640 |
Plasma SDMA/arginine concentration, calculated as SDMA/ARG AUC from 0-180 minutes (NCT02482675)
Timeframe: SDMA/ARG area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | (nmol/L)/(umol/L)*min (Mean) |
|---|---|
| Glucose | 175 |
| Glucose With Non-fat Milk | 31 |
| Glucose With Whey Protein Isolate | 4 |
| Glucose With Sodium Caseinate | -17 |
Plasma BH4/BH2 concentration, calculated as BH4/BH2 AUC from 0-180 minutes (NCT02482675)
Timeframe: Plasma BH4/BH2 concentration area under the curve for 3 hours (0, 30, 60, 90, 120, 150, 180 minutes) (change from baseline)
| Intervention | ratio*min (Mean) |
|---|---|
| Glucose | -47 |
| Glucose With Non-fat Milk | 78 |
| Glucose With Whey Protein Isolate | 171 |
| Glucose With Sodium Caseinate | 131 |
Flow mediated dilation (FMD) of the brachial artery, calculated as FMD AUC for 0-180 minutes (change from baseline) (NCT02482675)
Timeframe: Area under curve for FMD for three hours (0, 30, 60, 90, 120, 180 minutes)
| Intervention | %*min (Mean) |
|---|---|
| Glucose | -307 |
| Glucose With Non-fat Milk | -34.8 |
| Glucose With Whey Protein Isolate | -36.8 |
| Glucose With Sodium Caseinate | -110 |
5 reviews available for n(g),n(g')-dimethyl-l-arginine and Metabolic Syndrome
| Article | Year |
|---|---|
Emerging interface between metabolic syndrome and asthma.
Topics: Animals; Arginase; Arginine; Asthma; Humans; Hyperinsulinism; Inflammation; Insulin; Insulin Resista | 2011 |
Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?
Topics: Animals; Arginine; Cardiovascular Diseases; Endothelium, Vascular; Humans; Metabolic Syndrome | 2002 |
Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.
Topics: Animals; Arginine; Cardiovascular Diseases; Drug Evaluation, Preclinical; Endothelium, Vascular; Enz | 2005 |
[The best of epidemiology and cardiovascular prevention in 2005].
Topics: Arginine; Biomarkers; Cardiovascular Diseases; Diabetes Complications; Environmental Pollutants; Hum | 2006 |
[Coronary allograft vasculopathy: pathophysiological interaction between the immune system, infections and metabolic syndrome].
Topics: Animals; Arginine; Clinical Trials as Topic; Coronary Disease; Cytomegalovirus Infections; Disease M | 2007 |
7 trials available for n(g),n(g')-dimethyl-l-arginine and Metabolic Syndrome
| Article | Year |
|---|---|
Effects of virgin coconut oil consumption on metabolic syndrome components and asymmetric dimethylarginine: A randomized controlled clinical trial.
Topics: Adult; Arginine; Biomarkers; Blood Glucose; Coconut Oil; Dietary Fats; Female; Humans; Iran; Lipids; | 2021 |
Does Vitamin D Status Correlate with Cardiometabolic Risk Factors in Adults with Growth Hormone Deficiency?
Topics: 25-Hydroxyvitamin D 2; Adolescent; Adult; Aged; Aged, 80 and over; Arginine; Blood Glucose; C-Reacti | 2017 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Low-fat milk ingestion prevents postprandial hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic syndrome.
Topics: Adult; Animals; Area Under Curve; Arginine; Blood Glucose; Brachial Artery; Cross-Over Studies; Diet | 2013 |
Effects of an energy-restricted diet rich in plant-derived α-linolenic acid on systemic inflammation and endothelial function in overweight-to-obese patients with metabolic syndrome traits.
Topics: Adipokines; Adult; alpha-Linolenic Acid; Arginine; Biomarkers; C-Reactive Protein; Chitinase-3-Like | 2014 |
Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome.
Topics: Adult; Arginine; Cholesterol; Endothelium, Vascular; Fatty Acids, Monounsaturated; Female; Fluvastat | 2008 |
Prophylactics of erectile dysfunction in patients with metabolic syndrome.
Topics: Adult; Aged; Antibodies; Antihypertensive Agents; Arginine; Erectile Dysfunction; Humans; Hypoglycem | 2009 |
Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: the mefisto study.
Topics: Adult; Arginine; Carotid Arteries; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Me | 2008 |
20 other studies available for n(g),n(g')-dimethyl-l-arginine and Metabolic Syndrome
| Article | Year |
|---|---|
Associations of circulating dimethylarginines with the metabolic syndrome in the Framingham Offspring study.
Topics: Arginine; Biomarkers; Cross-Sectional Studies; Female; Humans; Male; Metabolic Syndrome; Middle Aged | 2021 |
The effect of exenatide (a GLP-1 analogue) and sitagliptin (a DPP-4 inhibitor) on asymmetric dimethylarginine (ADMA) metabolism and selected biomarkers of cardiac fibrosis in rats with fructose-induced metabolic syndrome.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Chromatography, Liquid; Dipeptidyl-Peptidase IV Inhi | 2023 |
Successful endodontic treatment reduces serum levels of cardiovascular disease risk biomarkers-high-sensitivity C-reactive protein, asymmetric dimethylarginine, and matrix metalloprotease-2.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; COVID-19; COVID-19 Vaccines; Glycated Hemog | 2023 |
The prognostic value of asymmetric dimethylarginine in patients with cardiac syndrome X.
Topics: Aged; Arginine; Endothelium, Vascular; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Progno | 2017 |
Association of endothelial dysfunction with cardiovascular risk factors and new-onset diabetes mellitus in patients with hypertension.
Topics: Aged; Arginine; Brazil; C-Reactive Protein; Cardiovascular Diseases; Diabetes Complications; Diabete | 2018 |
Endothelial function in patients with metabolic syndrome and erectile dysfunction: a question of angiopoietin imbalance?
Topics: Angiopoietin-1; Angiopoietin-2; Angiopoietins; Arginine; Biomarkers; Cross-Sectional Studies; Endoth | 2013 |
IGF-1 and ADMA levels are inversely correlated in nondiabetic ankylosing spondylitis patients undergoing anti-TNF-alpha therapy.
Topics: Adipokines; Antibodies, Monoclonal; Arginine; Female; Humans; Inflammation; Infliximab; Insulin-Like | 2014 |
Plasma levels of asymmetric dimethylarginine in premature neonates: its possible involvement in developmental programming of chronic diseases.
Topics: Arginine; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Female; Humans; Infan | 2009 |
Vascular biomarkers in the metabolic syndrome.
Topics: Arginine; Biomarkers; Blood Vessels; Endothelium, Vascular; Enzyme Inhibitors; Glycation End Product | 2009 |
Time course of asymmetric dimethylarginine (ADMA) and oxidative stress in fructose-hypertensive rats: a model related to metabolic syndrome.
Topics: Animals; Aorta; Arginine; Blood Glucose; Blood Pressure; Body Weight; Disease Models, Animal; Dose-R | 2011 |
Acute effects of hyperglycaemia on asymmetric dimethylarginine (ADMA), adiponectin and inflammatory markers (IL-6, hs-CRP) in overweight and obese women with metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Arginine; Biomarkers; Female; Humans; Hyperglycemia; Interleukin-6; Metabo | 2010 |
Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome.
Topics: Arginine; Body Mass Index; Case-Control Studies; Chile; Cholesterol, LDL; Female; Humans; Insulin Re | 2011 |
In vivo nitric oxide synthesis, insulin sensitivity, and asymmetric dimethylarginine in obese subjects without and with metabolic syndrome.
Topics: Adult; Arginine; Blood Glucose; Blood Pressure; Cholesterol, HDL; Female; Glucose Tolerance Test; Hu | 2012 |
Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy.
Topics: Adiposity; Adolescent; Albuminuria; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; A | 2012 |
Biological signatures of asymptomatic extra- and intracranial atherosclerosis: the Barcelona-AsIA (Asymptomatic Intracranial Atherosclerosis) study.
Topics: Aged; Arginine; Biomarkers; C-Reactive Protein; Carotid Artery Diseases; Cohort Studies; Cross-Secti | 2012 |
Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover.
Topics: Adult; Aged; Aged, 80 and over; Aging; Arginine; Blood Glucose; Body Composition; Female; Glucose; G | 2006 |
Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome.
Topics: Adolescent; Adult; Arginine; C-Reactive Protein; Colombia; Humans; Insulin Resistance; Male; Metabol | 2007 |
Reduced asymmetric dimethylarginine (ADMA) levels mediate in the protection from metabolic syndrome by smoking.
Topics: Arginine; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Smoking | 2008 |
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
Topics: Adult; Aged; Arginine; Cardiovascular Diseases; Cross-Sectional Studies; Enzyme Inhibitors; Female; | 2002 |
Insulin resistance, ADMA levels, and cardiovascular disease.
Topics: Arginine; Cardiovascular Diseases; Enzyme Inhibitors; Humans; Insulin Resistance; Metabolic Syndrome | 2002 |